tiakis Biotech AG Reports Clinical Phase Ib/II Trial Results of Tiprelestat for the Treatment of Hospitalized COVID-19 Patients
09. Dezember 2024 04:00 ET
|
AKAMPION
- Tiprelestat was safe and well tolerated, with initial signs of clinical efficacy Kiel, Germany, December 9, 2024 – tiakis Biotech AG, a clinical-stage biopharmaceutical company developing...
Thermosome Initiates Final Dose Level in Phase I Trial of Lead Compound THE001
04. Dezember 2024 04:00 ET
|
AKAMPION
Independent Data Safety Monitoring Board declared dose level 2 as safe and recommended escalation to final dose level 3 Munich, Germany – December 4, 2024 – Thermosome, a drug development company...
Thermosome Presents Encouraging Initial Clinical Data from Phase I Trial of Lead Compound THE001
19. November 2024 04:00 ET
|
AKAMPION
THE001 safe and well tolerated in first two dose level, demonstrating encouraging signs of clinical activityData presented at The Connective Tissue Oncology Society (CTOS) Annual Meeting 2024 Munich,...
Ebenbuild Appoints Charles A. Taylor, PhD as Chairman of the Board
11. November 2024 04:00 ET
|
AKAMPION
World renowned researcher and leader in predictive, simulation-based medicine to support further growth and strengthen footprint in the U.S. Munich, Germany, November 11, 2024 -- Ebenbuild, a company...
ANEUVO präsentiert wegweisendes Neuromodulationssystem ExaStim® auf der MEDICA 2024
06. November 2024 04:00 ET
|
AKAMPION
Neuartiges Produkt mit FDA Breakthrough Device Designation zur Behandlung chronischer RückenmarksverletzungenTechnologie wird in Halle 10 / H44 vorgestellt Düsseldorf, Deutschland – 6....
AMYRA Successfully Demonstrates a New Therapeutic Paradigm for Gluten-Related Disorders in a First-in-Human Study
23. Oktober 2024 04:00 ET
|
AKAMPION
Lead product AMYNOPEP achieves proof-of-principle in exploratory clinical studyAMYNOPEP is the first and only gluten-digesting enzyme combination that supports and enhances the activity of critical...
Preliminary Data of BellaSeno’s Clinical Trial on Scaffold-Guided Breast Regeneration Presented at the 93rd Annual Plastic Surgery Meeting in San Diego, CA
09. Oktober 2024 04:00 ET
|
AKAMPION
Performance: Statistically significant superiority over fat grafting, with breast volume retention twice as highSafety: BellaSeno’s scaffolds are safe and improve patient satisfaction and well-being ...
Mabylon AG Receives Research Grants Totaling More Than CHF 1.3 Million for Amyotrophic Lateral Sclerosis (ALS) and Inflammasome Programs
24. September 2024 04:00 ET
|
AKAMPION
Schlieren, Zurich/Switzerland, September 24, 2024 - Mabylon AG, a leader in the high-throughput discovery, characterization, and development of human-derived antibodies, today announced that it has...
ImmunOs Therapeutics AG Raises $11 Million and Further Strengthens Investor Base
17. September 2024 04:00 ET
|
AKAMPION
Existing investors and new investor Double Point Ventures join forces to support ImmunOs TherapeuticsInvestment secures funding of ongoing promising clinical trial of IOS-1002 in solid cancers ...
ImmunOs Therapeutics Expands Phase I Clinical Trial of IOS-1002 in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Solid Tumors
24. Juli 2024 04:00 ET
|
AKAMPION
Dosing of patients in new combination treatment arm – IOS-1002 plus KEYTRUDA Schlieren (Zurich Area), Switzerland – July 24, 2024 – ImmunOs Therapeutics AG, a biopharmaceutical company using its...